Technical Analysis for OPT - Opthea Ltd  

Grade Last Price % Change Price Change
B 0.740 0.00% 0.000
OPT closed unchanged on Thursday, March 28, 2024, on 3.85 times normal volume. The bulls were able to push the stock to a new 52-week high. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.
1 Watcher
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Up Up Up

Date Alert Name Type % Chg
New Uptrend Bullish 0.00%
Volume Surge Other 0.00%
New 52 Week High Strength 0.00%
Upper Bollinger Band Walk Strength 0.00%
Above Upper BB Strength 0.00%
Gapped Up Strength 0.00%
Overbought Stochastic Strength 0.00%
Pocket Pivot Bullish Swing Setup 0.00%
Volume Surge Other 0.00%
Calm After Storm Range Contraction 0.00%

   Recent Intraday Alerts

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Opthea Ltd   Description

Opthea Limited, formerly Circadian Technologies Limited, is engaged in developing and commercializing therapies primarily for eye diseases. The Company operates in medical technology and healthcare industry in Australia. The Company is involved in the development activities, which are based on the intellectual property portfolio covering key targets, such as vascular endothelial growth factors [VEGF]-C, -D and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, including angiogenesis and lymph angiogenesis respectively, as well as vascular leakage. It is developing its lead molecule, which is a soluble form of VEGFR-3 referred to as OPT-302, for the treatment of wet age-related macular degeneration (wet AMD). OPT-302 blocks two members of the vascular endothelial growth factor family, VEGF-C and VEGF-D, which cause blood vessels to grow and leak. It is investigating OPT-302 in an ongoing Phase I/IIA clinical trial in wet AMD patients.


Classification

Sector: Healthcare
Industry: Drug Manufacturers - Major
Keywords: Health Healthcare Disease Diseases Clinical Trial Intellectual Property Medical Technology Proteins Eye Diseases Macular Degeneration Healthcare Industry

Is OPT a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 0.787
52 Week Low 0.3125
Average Volume 484,394
200-Day Moving Average 0.500
50-Day Moving Average 0.597
20-Day Moving Average 0.653
10-Day Moving Average 0.670
Average True Range 0.036
RSI (14) 68.05
ADX 25.17
+DI 36.455
-DI 10.792
Chandelier Exit (Long, 3 ATRs) 0.681
Chandelier Exit (Short, 3 ATRs) 0.707
Upper Bollinger Bands 0.731
Lower Bollinger Band 0.576
Percent B (%b) 1.06
BandWidth 23.726
MACD Line 0.031
MACD Signal Line 0.022
MACD Histogram 0.0088
Fundamentals Value
Market Cap 249.87 Million
Num Shares 338 Million
EPS -0.09
Price-to-Earnings (P/E) Ratio -8.22
Price-to-Sales 0.00
Price-to-Book 11.98
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.811
Resistance 3 (R3) 0.818 0.803 0.799
Resistance 2 (R2) 0.803 0.785 0.799 0.795
Resistance 1 (R1) 0.771 0.774 0.764 0.764 0.791
Pivot Point 0.756 0.756 0.752 0.752 0.756
Support 1 (S1) 0.724 0.738 0.717 0.717 0.689
Support 2 (S2) 0.709 0.727 0.705 0.685
Support 3 (S3) 0.677 0.709 0.681
Support 4 (S4) 0.670